A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma

Peter Hosein, Michael D. Craig, Martin S. Tallman, Ralph V. Boccia, Brian L. Hamilton, Jonathan J. Lewis, Izidore Lossos

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Darinaparsin is a novel organic arsenic compound that is being developed to improve the efficacy and therapeutic index of arsenic as an antineoplastic agent. It has activity in preclinical models of hematological malignancies and we set out to test it in patients with refractory lymphoma. In this multicenter, Phase II trial, patients with relapsed or refractory Hodgkin (HL) and non-Hodgkin lymphoma (NHL) were treated with darinaparsin 300 mg/m 2 intravenously daily for five consecutive days every 28 days, for up to six cycles. The primary endpoint was the overall response rate. Twenty-nine heavily pretreated patients with lymphoma (22 with NHL and 7 with HL) were enrolled. There was one complete response (CR), one unconfirmed CR (CRu), three partial responses (PRs), and four with stable disease (SD), with an overall response rate of 17% (95% confidence interval (CI) 6-36%). Among the seven patients with peripheral T-cell lymphoma (PTCL), there was one CR, one CRu, and two with prolonged SD. The most common toxicities were fatigue, nausea, diarrhea, and anemia. Darinaparsin was safe and showed preliminary activity in this heavily pretreated population of relapsed/refractory lymphoma patients. Encouraging responses were seen in PTCL and further study in this subtype is planned.

Original languageEnglish
Pages (from-to)111-114
Number of pages4
JournalAmerican Journal of Hematology
Volume87
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Hodgkin Disease
Non-Hodgkin's Lymphoma
Peripheral T-Cell Lymphoma
Lymphoma
Arsenicals
Arsenic
Hematologic Neoplasms
Antineoplastic Agents
Nausea
Fatigue
Anemia
Diarrhea
darinaparsin
Confidence Intervals
Population
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma. / Hosein, Peter; Craig, Michael D.; Tallman, Martin S.; Boccia, Ralph V.; Hamilton, Brian L.; Lewis, Jonathan J.; Lossos, Izidore.

In: American Journal of Hematology, Vol. 87, No. 1, 01.01.2012, p. 111-114.

Research output: Contribution to journalArticle

Hosein, Peter ; Craig, Michael D. ; Tallman, Martin S. ; Boccia, Ralph V. ; Hamilton, Brian L. ; Lewis, Jonathan J. ; Lossos, Izidore. / A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma. In: American Journal of Hematology. 2012 ; Vol. 87, No. 1. pp. 111-114.
@article{abc4fdfc0cb84ebdae3699f8ec0b5f3f,
title = "A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma",
abstract = "Darinaparsin is a novel organic arsenic compound that is being developed to improve the efficacy and therapeutic index of arsenic as an antineoplastic agent. It has activity in preclinical models of hematological malignancies and we set out to test it in patients with refractory lymphoma. In this multicenter, Phase II trial, patients with relapsed or refractory Hodgkin (HL) and non-Hodgkin lymphoma (NHL) were treated with darinaparsin 300 mg/m 2 intravenously daily for five consecutive days every 28 days, for up to six cycles. The primary endpoint was the overall response rate. Twenty-nine heavily pretreated patients with lymphoma (22 with NHL and 7 with HL) were enrolled. There was one complete response (CR), one unconfirmed CR (CRu), three partial responses (PRs), and four with stable disease (SD), with an overall response rate of 17{\%} (95{\%} confidence interval (CI) 6-36{\%}). Among the seven patients with peripheral T-cell lymphoma (PTCL), there was one CR, one CRu, and two with prolonged SD. The most common toxicities were fatigue, nausea, diarrhea, and anemia. Darinaparsin was safe and showed preliminary activity in this heavily pretreated population of relapsed/refractory lymphoma patients. Encouraging responses were seen in PTCL and further study in this subtype is planned.",
author = "Peter Hosein and Craig, {Michael D.} and Tallman, {Martin S.} and Boccia, {Ralph V.} and Hamilton, {Brian L.} and Lewis, {Jonathan J.} and Izidore Lossos",
year = "2012",
month = "1",
day = "1",
doi = "10.1002/ajh.22232",
language = "English",
volume = "87",
pages = "111--114",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma

AU - Hosein, Peter

AU - Craig, Michael D.

AU - Tallman, Martin S.

AU - Boccia, Ralph V.

AU - Hamilton, Brian L.

AU - Lewis, Jonathan J.

AU - Lossos, Izidore

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Darinaparsin is a novel organic arsenic compound that is being developed to improve the efficacy and therapeutic index of arsenic as an antineoplastic agent. It has activity in preclinical models of hematological malignancies and we set out to test it in patients with refractory lymphoma. In this multicenter, Phase II trial, patients with relapsed or refractory Hodgkin (HL) and non-Hodgkin lymphoma (NHL) were treated with darinaparsin 300 mg/m 2 intravenously daily for five consecutive days every 28 days, for up to six cycles. The primary endpoint was the overall response rate. Twenty-nine heavily pretreated patients with lymphoma (22 with NHL and 7 with HL) were enrolled. There was one complete response (CR), one unconfirmed CR (CRu), three partial responses (PRs), and four with stable disease (SD), with an overall response rate of 17% (95% confidence interval (CI) 6-36%). Among the seven patients with peripheral T-cell lymphoma (PTCL), there was one CR, one CRu, and two with prolonged SD. The most common toxicities were fatigue, nausea, diarrhea, and anemia. Darinaparsin was safe and showed preliminary activity in this heavily pretreated population of relapsed/refractory lymphoma patients. Encouraging responses were seen in PTCL and further study in this subtype is planned.

AB - Darinaparsin is a novel organic arsenic compound that is being developed to improve the efficacy and therapeutic index of arsenic as an antineoplastic agent. It has activity in preclinical models of hematological malignancies and we set out to test it in patients with refractory lymphoma. In this multicenter, Phase II trial, patients with relapsed or refractory Hodgkin (HL) and non-Hodgkin lymphoma (NHL) were treated with darinaparsin 300 mg/m 2 intravenously daily for five consecutive days every 28 days, for up to six cycles. The primary endpoint was the overall response rate. Twenty-nine heavily pretreated patients with lymphoma (22 with NHL and 7 with HL) were enrolled. There was one complete response (CR), one unconfirmed CR (CRu), three partial responses (PRs), and four with stable disease (SD), with an overall response rate of 17% (95% confidence interval (CI) 6-36%). Among the seven patients with peripheral T-cell lymphoma (PTCL), there was one CR, one CRu, and two with prolonged SD. The most common toxicities were fatigue, nausea, diarrhea, and anemia. Darinaparsin was safe and showed preliminary activity in this heavily pretreated population of relapsed/refractory lymphoma patients. Encouraging responses were seen in PTCL and further study in this subtype is planned.

UR - http://www.scopus.com/inward/record.url?scp=84155169030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84155169030&partnerID=8YFLogxK

U2 - 10.1002/ajh.22232

DO - 10.1002/ajh.22232

M3 - Article

C2 - 22081459

AN - SCOPUS:84155169030

VL - 87

SP - 111

EP - 114

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -